The Senate approved a handful of amendments by unanimous consent on Wednesday (see below), and will hold about a dozen votes before coming to the final bill. The legislation, S. 3187, is generally non-controversial, and would reauthorize and extend a user-fee program that drug and medical device industry groups support as a way of speeding up the FDA approval process.
As part of a deal announced Wednesday, Republicans won the right to have a vote on their alternative plan, which would terminate a preventive health fund created in 2010.
But approval of both the GOP alternative and the Democratic bill will need 60 votes to pass. Because each party seems to genuinely hate the other's bill, the votes might well be a setup for partisan finger-pointing once both fail, which will at least give the parties something to talk about over the long Memorial Day weekend.
The Senate should also approve a 60-day extension of the National Flood Insurance Program at some point today. Senate Majority Leader Harry ReidHarry ReidSanders and Schumer are right: Ellison for DNC chair The Hill's 12:30 Report Hopes rise for law to expand access to experimental drugs MORE (D-Nev.) said Wednesday that he would agree to tackle a longer-term reform bill once the Senate returns from its Memorial Day week off.
Also up today, a likely vote on a bill to extend the National Flood Insurance Program (NFIP) for 60 days, also part of Wednesday's announcement.
In a unanimous-consent vote Wednesday, the Senate approved H.R. 4097, the John F. Kennedy Center Reauthorization Act, and the following six amendments to the FDA bill, from:
• Sen. Ben CardinBen CardinDem senator: Don't let leaks distract from real issue of Russian interference Washington-area lawmakers request GAO report on DC Metro Warren wants briefing on probe into Trump ally MORE (D-Md.), to ensure that adequate information is disseminated to healthcare providers and payers about the potential benefits and risks of medical products on all patient populations, particularly underrepresented sub-populations, including racial subgroups;
• Cardin, to require the commissioner of Food and Drugs to report to Congress on issues with respect to small businesses;
• Sen. Chuck GrassleyChuck GrassleyGOP senator grilled over DeVos vote during town hall Big Pharma must address high drug prices ObamaCare fix hinges on Medicaid clash in Senate MORE (R-Iowa), to provide employee protections for the Commissioned Corps of the Public Health Service Act;
• Grassley, to provide deadlines for the issuance of certain regulations and to require a GAO report on the implementation of the clinical trial registration and reporting requirements under the Public Health Service Act;
• Sen. Joe ManchinJoe ManchinDem 2020 hopefuls lead pack in opposing Trump Cabinet picks Manchin: Sanders backers should challenge me in Dem primary Greens launch ads against two GOP senators for Pruitt votes MORE (D-W.Va.), to reclassify the pain reliever hydrocodone under the Controlled Substances Act; and
• Sen. Jack ReedJack ReedA guide to the committees: Senate Cruz: Supreme Court 'likely' to uphold Trump order Schumer: Trump should see 'handwriting on the wall,' drop order MORE (D-R.I.), to make effective the proposed rule of the Food and Drug Administration relating to sunscreen drug products.